← ANALYST RATINGS · TIPRANKS
Tempus AI, Inc. Class A (TEM): analyst forecast and price target
Analyst consensus
Moderate Buy6 Buy5 Hold0 Sell
Ratings of 11 analysts in the last 3 months · top analysts only12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $75.00, the highest $95.00, the lowest $50.00. The average is +15.9% from the last price of $64.72.
Analyst ratings 21
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $45.00 → $70.00+55.6% | Hold | +8.2% | Reiterated | 14.10.26on TipRanks 06:10 | +1.2%next day +3.8% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $80.00 → $95.00+18.8% | Buy | +46.8% | Reiterated | 12.10.26on TipRanks 05:15 | −4.1%next day +0.3% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $52.00 → $75.00+44.2% | Hold | +15.9% | Reiterated | 09.10.26on TipRanks 08:25 | +1.8%next day −4.1% · 5 days −6.8% | ↗ |
| AI xAi Medical - Healthcare Information ServicesxAI Grok-3 | TipRanks - xAI | $76.00 → $74.00−2.6% | Hold | +14.3% | Reiterated | 08.10.26on TipRanks 15:05 | — | |
| AI DeepSeek Medical - Healthcare Information ServicesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $76.00 → $72.00−5.3% | Hold | +11.2% | Reiterated | 08.10.26on TipRanks 15:05 | — | |
| AI OpenAI Medical - Healthcare Information ServicesOpenAI 5.2 | TipRanks - OpenAI | $72.00 → $70.00−2.8% | Hold | +8.2% | Reiterated | 08.10.26on TipRanks 15:05 | — | |
| AI Anthropic Medical - Healthcare Information ServicesAnthropic Opus-4.5 | TipRanks - Anthropic | $73.00 → $72.00−1.4% | Hold | +11.2% | Reiterated | 08.10.26on TipRanks 15:05 | — | |
| AI Google Medical - Healthcare Information ServicesGemini 3-pro | TipRanks - Google | $76.00 → $74.00−2.6% | Hold | +14.3% | Reiterated | 08.10.26on TipRanks 15:05 | — | |
| AI PerPlexity Medical - Healthcare Information ServicesPerPlexity SonarPro | TipRanks - PerPlexity | $74.00 → $71.00−4.1% | Hold | +9.7% | Reiterated | 08.10.26on TipRanks 15:05 | — | |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $65.00 → $92.00+41.5% | Buy | +42.2% | Reiterated | 01.10.26on TipRanks 08:35 | −6.8%next day −0.6% · 5 days −10.7% | ↗ |
| Evie Koslosky★★★★★★★★★★#9740 · hits 58% · avg −3.1% | Goldman Sachs | $75.00 | Hold | +15.9% | Initiated | 22.09.26on TipRanks 05:00 | −1.1%next day −0.1% · 5 days +8.2% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $56.00 → $66.00+17.9% | Buy | +2.0% | Reiterated | 11.09.26on TipRanks 06:10 | −0.4%next day +5.9% · 5 days +32.0% | ↗ |
| Unknown Analyst | UBS | $70.00 | Hold | +8.2% | Initiated | 08.09.26on TipRanks Sep 11 06:10 | 0.0%next day −4.2% · 5 days +8.2% | ↗ |
| Jamie Clark★★★★★★★★★★#6680 · hits 75% · avg +5.9% | Rothschild & Co Redburn | $67.00 | Hold | +3.5% | Initiated | 08.09.26on TipRanks 05:25 | 0.0%next day −4.2% · 5 days +8.2% | ↗ |
| Sarah James★★★★★★★★★★#2265 · hits 55% · avg +5.7% | Cantor Fitzgerald | $80.00 | Buy | +23.6% | Initiated | 02.09.26on TipRanks 08:00 | −1.0%next day +3.3% · 5 days −4.2% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $56.00 → $76.00+35.7% | Buy | +17.4% | Upgrade | 01.09.26on TipRanks 05:15 | −0.5%next day −1.0% · 5 days −1.7% | ↗ |
| Eugene Mannheimer★★★★★★★★★★#3417 · hits 51% · avg +6.8% | Freedom Capital Markets | $51.00 → $73.00+43.1% | Hold | +12.8% | Reiterated | 31.08.26on TipRanks Sep 27 05:10 | −1.2%next day −0.5% · 5 days +2.1% | ↗ |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $70.00 → $80.00+14.3% | Buy | +23.6% | Reiterated | 20.08.26on TipRanks 07:30 | +9.7%next day +8.7% · 5 days +4.9% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $60.00 → $50.00−16.7% | Hold | −22.7% | Reiterated | 03.08.26on TipRanks 06:55 | +3.5%next day +0.4% · 5 days +17.5% | ↗ |
| Catherine Ramsey Schulte★★★★★★★★★★#864 · hits 53% · avg +11.2% | Robert W. Baird | $67.00 → $59.00−11.9% | Buy | −8.8% | Reiterated | 31.07.26on TipRanks 07:38 | −1.7%next day +3.5% · 5 days +15.1% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Hold | — | Assigned | 31.07.26on TipRanks 06:38 | −1.7%next day +3.5% · 5 days +15.1% | ↗ |
| Ryan MacDonald★★★★★★★★★★#12366 · hits 37% · avg −11.1% | Needham | $75.00 | Buy | +15.9% | Reiterated | 31.07.26on TipRanks 05:42 | −1.7%next day +3.5% · 5 days +15.1% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $68.00 → $71.00+4.4% | Buy | +9.7% | Reiterated | 15.07.26on TipRanks 09:01 | −2.8%next day −5.9% · 5 days −17.0% | ↗ |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $70.00 | Buy | +8.2% | Reiterated | 10.07.26on TipRanks 04:00 | −5.7%next day −3.2% · 5 days −8.3% | ↗ |
| Paige Chamberlain★★★★★★★★★★#7338 · hits 100% · avg +13.9% | Wolfe Research | — | Hold | — | Initiated | 01.06.26on TipRanks Jun 2 07:17 | +4.3%next day −6.2% · 5 days −5.4% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $49.00 → $100+104.1% | Buy | +54.5% | Reiterated | 13.04.26on TipRanks 10:55 | +6.1%next day +6.5% · 5 days +20.2% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $35.00 | Sell | −45.9% | Initiated | 12.04.26on TipRanks 19:55 | +6.1%next day +6.5% · 5 days +20.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Tempus AI, Inc. Class A
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $69.47 at a price of $81.90 (−15.2%); now: $73.53 at $64.72 (+13.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 4 | 4 | 5 | 3 | 2 |
| Buy | 8 | 8 | 11 | 8 | 9 | 7 |
| Hold | 5 | 10 | 15 | 15 | 11 | 7 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 02.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.07 (from $-0.17 to $0.00). Last quarter: $-0.04.
Sales
Next quarter’s sales estimate — $409M (from $397M to $420M). Last quarter: $382M.
Best top-analyst consensus in the sector · Healthcare
About Tempus AI, Inc. Class A
- CEO: Eric Lefkofsky
- Employees: 3,800
- 600 West Chicago Avenue, Chicago, IL, 60654, US
- www.tempus.com
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Data from the stock’s TipRanks forecast page, read 11 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗